Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/20/19
End: 08/28/24
Due: 08/28/25
Phase: N/A
Priority: Normal
Start: 10/29/18
End: 02/23/26
Due: 02/23/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) | NCT03324373 | Yousef Zakharia | user2@example.com | None | 2019-03-20 | 2024-08-28 | 2025-08-28 | - | - | 2025-07-14 |
| A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer | NCT03575013 | Yousef Zakharia | user2@example.com | None | 2018-10-29 | 2026-02-23 | 2027-02-23 | - | - | 2025-07-14 |